Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs CTL 119 (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 06 Jun 2017 Results (n=10) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 30 May 2017 Results from this trial published in a Novartis media release.
- 30 May 2017 According to a Novartis media release, data from this trial will be presented the upcoming 53rd Annual Meeting of the American Society of Clinical Oncology.